<DOC>
	<DOCNO>NCT02869659</DOCNO>
	<brief_summary>This randomize controlled clinical trial use methylomic transcriptomic profiling examine effect weight loss intervention cholesterol metabolism gene network monocyte adipocytes investigate longitudinal relationship modification glycemic improvement .</brief_summary>
	<brief_title>Valued EpiGenetic Glycemic ImprovEments Through Weight Loss</brief_title>
	<detailed_description>The investigator plan recruit total 200 middle-aged ( 40-65 year ) obese ( BMI=30-39.9 kg/m2 ) , sedentary , pre-diabetic participant randomize either 18-week dietary weight loss ( n=100 ) follow 8-week transition 26 week maintenance ( Weight Loss group ) delay weight loss ( Control group , n=100 ) intervention . During screen visit , eligible participant provide informed consent complete 3-day food record start 3-day run-in period use Medifast® meal replacement product use weight loss intervention . At next visit participant meet Registered Dietitian ( RD ) undergo assessment Readiness Change ( 18 ) . All participant must approve eligibility RD base clinical judgment likelihood success weight loss , likelihood compliance Medifast® meal plan , willingness randomize either group . Control/Delayed Weight Loss Group : ( 18 week ) Participants randomize delayed weight loss intervention ( n=100 ) serve no-weight loss control weight loss group first 18 week study . During control ( 18 week ) phase participant receive monthly phone call visit staff maintain contact interest study . At end initial 18 week participant complete follow assessment prior offer opportunity participate weight loss program . This weight loss program involve 18 weekly , group dietary exercise session lead study staff participant follow modify Diabetes Prevention Program . Participants give individual introduction session weight loss program study staff guide RD food purchase preparation meal , meal replacement supplement provide . Weight Loss group : Phase 1 ( 18 week ) : Participants assign group undergo dietary intervention first 18 week study design elicit approximate 8-10 % weight loss . The intervention incorporate partial meal replacement , nutrition education , behavior modification . This level weight loss achieve combination partial meal replacement ( MR ) program individual group nutrition/behavioral counseling . Participants provide asked consume 4 Medifast® MR per day . All participant follow Medifast Achieve TM 4 &amp; 2 &amp; 1 Plan® include 4 MR product per day , addition 2 Lean Green™ Meals 1 Healthy Snack . The Lean Green™ Meals prepare participant consist 5-7 oz . lean protein , 3 serving non-starchy vegetable 2 serving healthy fat . The Healthy Snack consist one serve fruit , dairy , grain . Each MR Medifast® contain ~90-110 kcals 10-15 g protein . Participants give individual introduction meal plan prior start guide RD food purchase preparation Lean Green TM meal . They encourage consume approve Medifast Achieve TM 4 &amp; 2 &amp; 1 Plan® . Phase 2 ( 8 week ) : After completion active weight loss phase , participant group attend bimonthly group meeting discuss increase activity . The goal participant slowly increase activity 150 minute per week continue 150 minute per week help maintain weight . Activity log dispense topic track activity , find time fitness get active discuss . Participants option transition meal replacement potentially continue select transition phase . Additional dietary guidance available help participant transition MR maintain weight . The RD calculate individual maintenance calorie goal discuss participant brief individual session prior start transition phase . At session introduction transition phase information track activity also discuss . Phase 3 ( 26 week ) : After completion phase 2 , participant call monthly 26 week ask return maintenance visit end 52 week study start . Participants offer optional session staff member time exit discus long term goal strategy provide closure .</detailed_description>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<criteria>BMI=3045.0 kg/m2 OR BMI 2730 , waist circumference ≥ 40in men ≥ 35in woman Sedentary past 6 mo ( &lt; 20 min ; 2 d/wk resistance aerobic exercise ) Normal cognitive function : Greater 12 year education : Caucasian MOCA ≥ 24 African American/Hispanic/Other MOCA ≥ 22 12 year less education : Caucasian MOCA ≥22 African American/Hispanic/Other MOCA ≥20 No evidence clinical depression Fasting blood glucose 100125 mg/dl OR Hemoglobin A1c 5.7 % 6.4 % No contraindication participation weight loss Able provide transportation study visit intervention Approved participation Medical Director Negative pregnancy test confirm postmenopausal/surgically sterile status ( Women Only ) Not involve research study Willing provide inform consent Weight loss ( ±5 % ) past 6 month Uncontrolled arrhythmias Cancer require treatment past year , except nonmelanoma skin cancer Regular smoker ( &gt; 1 cigarette/day ) heavy drinker ( &gt; 9 alcoholic drinks/wk ) within past year Insulin dependent uncontrolled diabetes ( FBG &gt; 126 mg/dl ) OR ( Hemoglobin A1c 6.5 % great ) Uncontrolled hypertension ( BP &gt; 160/90 mmHg ) Elevated triglyceride ( TG &gt; 400 mg/dl ) Clinically evident liver disease , kidney disease , edema anemia Past current ischemic heart disease , uncontrolled angina , heart failure , PAD , stroke , chronic respiratory disease , endocrine metabolic disease , neurological hematological disease Regular use growth/steroid hormone , include estrogen replacement , weight loss medication , diabetes medication include insulin and/or blood thinner History type bariatric weight loss surgery bilateral oophorectomy require long term hormone replacement therapy use</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>obesity</keyword>
	<keyword>pre-diabetes</keyword>
	<keyword>overweight</keyword>
	<keyword>lifestyle change</keyword>
	<keyword>glucose</keyword>
</DOC>